Comparison of efficacy and safety between generic and brand formulations of ceftriaxone
- At: 2008 FIP Congress in Basel (Switzerland)
- Type: Poster
- By: CHEN, Yi-Hsiu (Tzu Chi General Hospital Taipei Branch, Taipei, China Taiwan)
- Co-author(s): Wu, Ta-Wei (Tzu Chi General Hospital Taipei Branch, TAIPEI, China Taiwan)
After altering the manufacturer of ceftriaxone on Aug 6 2007, physicians responded that the clinical outcomes of brand formulations (denoted Ceftriaxone-B) were more superior than generic formulations (denoted Ceftriaone-G ). In our pilot study, fever reduction attained in 10/34 (29.4%) patients after using Ceftriaxone-B and in 6/36 (16.7%).. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.